OakChart

Harmony Biosciences Holdings Inc

HRMYHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 8:06 AM ET

33.80+0.25 (0.75%)
2026-11-11 14:22 CET
Market cap
1,970.16 USD m
Revenue, TTM
989.36 USD m
Net income, TTM
178.60 USD m
Free cash flow, TTM
322.93 USD m
EPS diluted, TTM
3.03
P/E
11.17
Compare

Price

HRMY against its 20, 50 and 200-day averages
2050200beatmiss
30.0035.0040.001.9M3.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26HRMYclose 33.8020-day 36.4850-day 38.98200-day 34.6033.80

22.3% under 43.49 on 3 Sep 2026. Last 15 sessions, 23.9% high to low

Profile

HRMY
52-week range, 45% of the way up
25.9043.49

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

IndexRUT
Employees293
IPOAug 19, 2020
Beta1.00
ATR, 14d1.78
Rel volume0.06
Short float13.17%
Insider own13.80%
Inst own99.55%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.98B
Enterprise Value1.45B
Income178.60M
Sales989.36M
Book/sh18.26
Cash/sh13.13
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees293
IPOAug 19, 2020

Ratios

P/E11.17
Forward P/E8.41
PEG0.46
P/S2.01
P/B1.85
P/C2.57
P/FCF6.15
EV/EBITDA5.91
EV/Sales1.46
Quick Ratio3.42
Current Ratio3.44
Debt/Eq0.22
LT Debt/Eq0.12
Option/ShortYes / Yes

Earnings

EPS (ttm)3.03
EPS next Y4.02
EPS next Q1.10
EPS this Y37.58%
EPS next Y7.85%
EPS next 5Y18.24%
EPS past 3/5Y-3.00% -
Sales past 3/5Y25.64% 40.30%
EPS Y/Y TTM-4.89%
Sales Y/Y TTM19.79%
EPS Q/Q-6.78%
Sales Q/Q12.30%
EarningsNov 04 BMO
EPS/Sales Surpr.-25.53% -1.15%

Ownership

Insider Own13.80%
Insider Trans-0.89%
Inst Own99.55%
Inst Trans-0.51%
ROA13.30%
ROE18.73%
ROIC14.81%
Gross Margin71.62%
Oper. Margin22.17%
Profit Margin18.05%
SMA20-7.35%
SMA50-13.30%
SMA200-2.32%
Trades-

Technical

Shs Outstand58.72M
Shs Float50.62M
Short Float13.17%
Short Ratio6.77
Short Interest6.66M
52W High43.49 -22.28%
52W Low25.90 30.49%
Volatility6.01% 4.84%
ATR (14)1.78
RSI (14)35.62
Beta1.00
Rel Volume0.06
Avg Volume984.56K
Volume2,812

Performance

Perf Week-1.79%
Perf Month-8.72%
Perf Quarter-12.21%
Perf Half Y9.63%
Perf YTD-9.67%
Perf Year2.49%
Perf 3Y42.14%
Perf 5Y-20.51%
Perf 10Y-
Recom1.75
Target Price48.08
Prev Close33.55
Price33.80
Change %0.75%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 15, 2026InitiatedLLadenburg ThalmannBuy$55+62.7%
Aug 26, 2026InitiatedWWolfe ResearchOutperform$60+77.5%
Feb 23, 2026DowngradeTTruistBuy → Hold
Feb 23, 2026DowngradeDDeutsche BankBuy → Hold
Feb 11, 2026ResumedUUBSNeutral$46+36.1%
Jul 21, 2025InitiatedTTruistBuy$48+42.0%
Jul 10, 2025ResumedGGoldmanNeutral$33-2.4%
Jun 02, 2025ResumedOOppenheimerOutperform$61+80.5%
Feb 11, 2025InitiatedDDeutsche BankBuy$55+62.7%
Dec 17, 2024InitiatedHH.C. WainwrightBuy$75+121.9%

Peers

Mkt cap
TickerCompanyMkt cap
JAZZJazz Pharmaceuticals plc15.73B
AXSMAxsome Therapeutics Inc7.47B
ALKSAlkermes plc7.79B
ACADAcadia Pharmaceuticals Inc3.15B
APMDApnimed Inc660.26M
SUPNSupernus Inc5.97B
NBIXNeurocrine Biosciences Inc17.11B
TAKTakeda Pharmaceutical Co ADR67.19B
INDVIndivior Pharmaceuticals Inc5.97B
ANIPANI Pharmaceuticals Inc1.63B

Insider trading

latest 14 of 45
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Budur KumarCHIEF MEDICAL OFFICERSep 18 '26Option Exercise30.3935,8521,089,61148,967Sep 18 04:48 PM
Budur KumarCHIEF MEDICAL OFFICERSep 16 '26Option Exercise30.481,80054,86414,915Sep 18 04:48 PM
Budur KumarCHIEF MEDICAL OFFICERSep 17 '26Option Exercise30.4880024,38413,915Sep 18 04:48 PM
Budur KumarCHIEF MEDICAL OFFICERSep 18 '26Sale43.0535,8521,543,59013,115Sep 18 04:48 PM
Budur KumarCHIEF MEDICAL OFFICERSep 16 '26Sale43.011,80077,42613,115Sep 18 04:48 PM
Budur KumarCHIEF MEDICAL OFFICERSep 17 '26Sale43.0080034,40013,115Sep 18 04:48 PM
KUMAR BUDUROfficerSep 18 '26Proposed Sale42.7435,8521,532,314Sep 18 04:19 PM
KUMAR BUDUROfficerSep 17 '26Proposed Sale42.2180033,768Sep 17 04:34 PM
KUMAR BUDUROfficerSep 16 '26Proposed Sale42.171,80075,906Sep 16 04:33 PM
Budur KumarCHIEF MEDICAL OFFICERSep 08 '26Option Exercise30.4922,954699,94236,069Sep 09 05:12 PM
Budur KumarCHIEF MEDICAL OFFICERSep 08 '26Sale42.9628,4541,222,25813,115Sep 09 05:12 PM
Budur KumarCHIEF MEDICAL OFFICERSep 04 '26Sale41.985,500230,91118,615Sep 09 05:12 PM
KUMAR BUDUROfficerSep 08 '26Proposed Sale42.2528,4541,202,182Sep 08 04:29 PM
KUMAR BUDUROfficerSep 04 '26Proposed Sale41.865,500230,230Sep 04 04:31 PM

Held by

AUM
TickerCompanyAUM
IJRiShares Core S&P Small-Cap ETFAUM: 106.63B
AVUVAvantis U.S. Small Cap Value ETFAUM: 32.40B
VTIVanguard Morningstar Total Stock Market ETFAUM: 689.41B
VBVanguard Morningstar Small-Cap ETFAUM: 79.96B
IWMiShares Russell 2000 Index FundAUM: 78.30B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.85B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.56B
DFATU.S. Targeted Value Portfolio-ETF Class SharesAUM: 14.50B
VXFVanguard Extended Market Index ETFAUM: 30.61B
DFSVUS Small Cap Value Portfolio ETF Class SharesAUM: 8.54B

News

latest 14 of 206
  • Harmony Biosciences Misses As Royalty Costs Squeeze Margins And WAKIX Growth Cools, With February Patent Rulings Looming (Earnings Whispers) -7.04%
  • Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile (GlobeNewswire)
  • Harmony Biosciences Must Prove WAKIX Momentum Can Carry Street To Top Of Guidance (Earnings Whispers)
  • Revisiting Former Stock Picks Marriott, Logitech, Harmony Biosciences (Barrons.com) -5.95%
  • Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026 (GlobeNewswire)
  • Loading…
  • Harmony Bio CEO Plans His Exit, And Shares Take An Unharmonious Hit (Investor's Business Daily) -5.09%
  • Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth (GlobeNewswire)
  • Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days (GlobeNewswire)
  • Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress (GlobeNewswire)
  • Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference (GlobeNewswire)
  • Intuit downgraded, SolarEdge upgraded: Wall Street's top analyst calls (The Fly)
  • Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium (GlobeNewswire)
  • Harmony Biosciences Holdings Inc (HRMY) (Q2 2026) Earnings Call Highlights: Record Revenue and ... (GuruFocus.com) +8.93%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-040.8101.0880.810268.92272.0512
2026Q22026-08-041.2800.9561.284261.28250.7710
2026Q12026-05-070.5500.6950.553215.39220.8410
2025Q42026-02-240.3800.8760.383243.78240.3311
2025Q32025-11-040.8700.8110.866239.48226.8711
2025Q22025-08-050.6800.7050.681200.49204.2310
2025Q12025-05-060.7800.6070.779184.73182.279
2024Q42025-02-250.8500.7340.850201.27200.999
2024Q32024-10-290.7900.6650.793186.04184.078
2024Q22024-08-060.200-0.0020.201172.81172.536
2024Q12024-04-300.6700.6040.666154.62154.17
2023Q42024-02-220.4500.7220.452168.41169.025
2023Q32023-10-310.6300.6660.634160.27147.839
2023Q22023-08-010.5600.6090.565134.22142.018
2023Q12023-05-020.4800.4710.482119.13120.148
2022Q42023-02-210.7900.5840.787128.31127.667

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-2.480-0.585-1.122159.74155.21
2021FY0.5800.6400.584305.44303.77
2022FY2.9702.7872.970437.86436.79
2023FY2.1302.4162.134582.02582.76
2024FY2.5102.3552.514714.73714.38
2025FY2.7103.2032.710868.45865.06
2026FY-3.728--1,028
2027FY-4.021--1,179
2028FY-4.479--1,301
2029FY-6.253--1,453
2030FY-5.005--1,139

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-091232281.57271.35292
2026Q4S2026-11-041232281.8271.35292
2026Q4S2026-10-281202280.05271.35289.3
2026Q4S2026-10-271202280.05271.35289.3
2026Q4S2026-10-261201280.98271.35289.3
2026Q4S2026-10-181200281.79271.35289.5
2026Q4S2026-10-141222281.79271.35289.5
2026Q4S2026-10-131122282.74274.98289.5
2026Q4S2026-10-061132282.74274.98289.5
2026Q4S2026-09-281133282.74274.98289.5
2026Q4S2026-09-091134282.74274.98289.5
2026Q4S2026-08-311144282.74274.98289.5
2026Q4S2026-08-251144282.74274.98289.5
2026Q4S2026-08-041044283.16274.98289.5

Estimate history

EPS, annual-1.101-3.291-1.1220.5842.972.1342.5142.7113.0272
Period20182019202020212022202320242025TTM
EPS, quarterly0.7930.850.7790.6810.8660.3830.5531.2840.808
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual05.995159.742305.44437.855582.022714.734868.453989.36
Period20182019202020212022202320242025TTM
Sales, quarterly186.038201.267184.733200.489239.455243.776215.387261.28268.917
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual63.67856.88956.89158.82659.61656.76957.14557.72658.72
Period20182019202020212022202320242025MRQ
Shares, quarterly57.03157.14557.39457.53857.59657.72657.86758.12158.72
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue989.36868.45714.73582.02437.86305.44159.746.000.00
Cost of Goods Sold Incl. D&A280.79222.19180.66145.08106.4573.9427.744.790.18
Gross Profit708.57646.27534.07436.94331.41231.50132.001.21-0.18
Selling, General and Administrative Excl. Other489.21437.80343.25244.91211.22143.97115.02147.1141.26
Research and Development237.57189.59145.8276.0670.8930.3719.4569.5912.37
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income219.36208.47190.83192.03120.1987.5316.99-145.90-41.44
Interest Expense12.9114.6517.5023.7618.8024.1928.226.07-
Unusual Expense0.000.000.009.770.0026.1522.640.000.00
Net Income Before Taxes232.96215.06191.80173.40104.6937.43-36.94-151.98-39.90
Income Taxes54.3656.3846.3144.54-76.782.830.000.000.00
Consolidated Net Income178.60158.69145.49128.85181.4734.60-36.94-151.98-39.90
Net Income From Continuing Operations178.60158.69145.49128.85181.4734.60-36.94-151.98-39.90
Net Income178.60158.69145.49128.85181.4734.60-63.85-187.21-70.08
EPS (Recurring)2.992.712.512.252.970.89-0.84-3.29-1.10
EPS (Basic, Before Extraordinaries)3.082.762.562.173.070.60-1.12-3.29-1.10
EPS (Diluted)3.032.712.512.132.970.58-1.12-3.29-1.10
EBITDA244.70233.80214.94216.39143.57106.3727.22-142.69-41.26
Non-Operating Income (Expense)26.5121.2418.4714.893.290.24-3.070.001.54
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense30.2635.5233.7324.6526.9116.115.199.911.08
Price To Earnings Ratio11.0811.0816.2913.0921.5773.96---
Price To Sales Ratio2.372.522.793.357.698.2712.87--
Gross Margin71.6274.4274.7275.0775.6975.7982.6420.15-
Operating Margin22.1724.0026.7032.9927.4528.6610.63-2,433.76-
Net Margin18.0518.2720.3622.1441.4411.33-39.97-3,122.74-
Shares Outstanding58.7257.7357.1456.7759.6258.8356.8956.8963.68
Market Capitalization1,970.161,970.161,962.451,891.873,268.402,493.222,056.542,074.75-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue268.92261.28215.39243.78239.46200.49184.73201.27
Cost of Goods Sold Incl. D&A86.6569.1650.4774.5165.6144.1137.9560.37
Gross Profit182.27192.12164.91169.27173.84156.38146.78140.90
Selling, General and Administrative Excl. Other128.07102.81127.62130.71108.36108.1990.5385.17
Research and Development71.6646.6069.3849.9354.9650.1634.5434.67
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income54.2089.3237.2938.5665.4948.1856.2455.73
Interest Expense3.063.073.233.553.623.653.844.21
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes59.2593.2739.6940.7667.4949.6457.1856.16
Income Taxes11.0517.837.2018.2716.629.8611.626.68
Consolidated Net Income48.2075.4332.4922.4950.8739.7845.5649.48
Net Income From Continuing Operations48.2075.4332.4922.4950.8739.7845.5649.48
Net Income48.2075.4332.4922.4950.8739.7845.5649.48
EPS (Recurring)0.811.280.550.380.870.680.780.85
EPS (Basic, Before Extraordinaries)0.831.300.560.390.880.690.800.87
EPS (Diluted)0.811.280.550.380.870.680.780.85
EBITDA60.1695.2843.2645.9971.4554.1562.2161.70
Non-Operating Income (Expense)8.117.025.635.755.625.104.774.64
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense6.427.578.148.138.559.009.847.79
Price To Earnings Ratio11.0814.6610.3411.788.8812.0513.2216.29
Price To Sales Ratio2.372.231.832.531.962.392.612.80
Gross Margin67.7873.5376.5769.4472.6078.0079.4570.00
Operating Margin20.1534.1817.3115.8227.3524.0330.4527.69
Net Margin17.9228.8715.089.2221.2419.8424.6624.58
Shares Outstanding58.7258.1257.8757.7357.6057.5457.3957.14
Market Capitalization1,970.162,107.871,620.122,155.261,585.601,814.611,903.301,962.45

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments775.34467.19353.46323.12234.31228.6324.4683.52
Short Term Receivables96.7983.0374.1454.7434.8422.184.250.00
Inventories5.367.205.364.304.433.821.090.00
Other Current Assets29.5321.8418.1118.1310.868.261.703.16
Total Current Assets907.01579.25451.07400.29284.44262.8931.5086.68
Net Property, Plant & Equipment5.343.382.712.884.120.941.331.58
Total Investments and Advances107.40109.1472.4423.320.750.750.750.50
Intangible Assets89.42113.26137.11160.95143.92162.3472.190.00
Deferred Tax Assets149.70190.40144.1685.94----
Other Assets12.763.763.950.490.220.150.940.52
Total Assets1,271.63999.20811.45673.87433.44427.07106.7089.28
Short Term Debt Incl. Current Port. of LT Debt86.8969.3116.442.002.000.000.000.00
Accounts Payable17.6913.7417.733.791.002.566.361.46
Other Current Liabilities147.5592.02129.6173.1050.77131.9813.535.77
Total Current Liabilities252.13175.08163.7878.8853.77134.5419.897.23
Long Term Debt148.18163.84179.65190.62192.22194.25509.22324.20
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities1.111.121.031.530.941.100.450.52
Total Liabilities401.41340.05344.46271.03246.94329.89529.57331.95
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity870.22659.15466.99402.84186.5197.18-422.86-242.67
Total Shareholders Equity870.22659.15466.99402.84186.5197.18-422.86-242.67
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity870.22659.15466.99402.84186.5197.18-422.86-242.67
Total Liabilities & Stockholders Equity1,271.63999.20811.45673.87433.44427.07106.7089.28
Book Value Per Share15.0711.538.236.763.171.71-7.43-3.81
Tangible Book Value Per Share13.539.555.814.060.72-1.15-8.70-3.81
Full-Time Employees293268246200180150150-
Price to Book Ratio1.843.293.939.5013.4521.1621.94-
Return on Assets13.9816.0717.3532.788.04-13.84-155.09-
Return on Equity20.7525.8429.6361.5824.39---
Return on Invested Capital15.5817.6819.9330.589.14-12.68-175.98-48.94
Quick Ratio3.583.272.725.025.211.931.5311.99
Current Ratio3.603.312.755.075.291.951.5811.99

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income178.60158.69145.49128.85181.4734.60-36.94-151.98-39.90
Depreciation25.3425.3424.1124.3623.3918.8410.243.210.18
Other Funds (Non Cash)100.6979.6686.8344.5629.6644.4935.3565.041.08
Funds from Operations300.34256.38227.14184.35148.5797.938.64-83.73-38.63
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital22.7091.82-7.3235.03-4.110.63-11.638.29-0.16
Cash from Operating Activities323.04348.20219.82219.39144.4798.56-2.98-75.44-38.80
Capital Expenditures-19.36-19.56-27.65-0.31-40.17-0.30-0.00-75.15-1.34
Net Assets From Acquisitions0.000.00-33.07-36.970.00-100.00-2.00-52.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-273.75-5.09-6.76-9.16-101.660.000.000.000.00
Purchase of Investments-388.78-86.15-105.29-127.47-110.730.000.000.000.00
Sale Or Maturity of Investments115.0481.0698.53118.319.070.000.000.000.00
Other Uses-32.00-15.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-325.11-39.65-67.48-46.44-141.83-100.30-2.00-127.15-1.34
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock26.4710.216.50-94.948.8439.07135.5748.9521.61
Repurchase of Common Pref Stock0.000.000.00-100.000.000.00-0.17-1.13-3.38
Sale of Common Pref Stock26.4710.216.505.058.8439.07135.7350.0925.00
Proceedsfrom Stock Options0.000.000.000.000.0029.70-12.1950.0025.00
Issuance or Reduction of Debt, Net-20.00-16.25-15.00-10.09-2.00190.35194.2094.820.00
Change in Long Term Debt-20.00-16.25-15.00-10.09-2.00190.35194.2094.820.00
Issuance of Long Term Debt0.000.000.00197.000.00190.85194.2094.820.00
Reduction of Long Term Debt-20.00-16.25-15.00-207.10-2.00-0.500.000.000.00
Net Financing Active Other Cash Flow-4.30-3.00-2.50-0.510.00-222.00-120.600.000.00
Other Financing Activities Uses-4.30-3.00-2.50-0.510.00-222.00-120.600.000.00
Cash from Financing Activities2.17-9.05-11.00-105.556.847.42209.16143.7721.61
Net Change in Cash0.10299.50141.3467.409.475.68204.17-58.82-18.53
Free Cash Flow322.93347.89218.67219.07144.2998.26-2.99-75.58-40.14
Preferred Dividends (Cash Flow)-0.000.000.000.000.00---
Price to Free Cash Flow7.266.309.118.9023.3325.69---
Deferred Taxes & Investment Tax Credit--7.30-29.30-13.42-85.940.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments771.14667.79640.92775.34672.58565.27
Short Term Receivables127.74111.00108.2296.79100.6592.98
Inventories5.876.365.285.366.886.10
Other Current Assets30.0829.1924.4029.5358.6927.00
Total Current Assets934.83814.33778.82907.01838.80691.35
Net Property, Plant & Equipment5.435.845.395.342.672.65
Total Investments and Advances280.74294.94229.82107.40106.10107.28
Intangible Assets71.5377.5083.4689.4295.38101.34
Deferred Tax Assets161.37156.76153.56149.70157.07201.19
Other Assets24.3523.7120.7712.768.194.19
Total Assets1,478.241,373.081,271.821,271.631,208.221,108.01
Short Term Debt Incl. Current Port. of LT Debt99.6982.2363.1786.8978.1555.38
Accounts Payable26.9221.6828.6017.6926.3428.30
Other Current Liabilities144.93130.16125.57147.55118.9196.45
Total Current Liabilities271.54234.07217.34252.13223.40180.13
Long Term Debt133.54138.74143.34148.18148.91153.78
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.931.030.791.110.781.02
Total Liabilities406.01373.84361.48401.41373.10334.93
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1,072.23999.24910.35870.22835.12773.08
Total Shareholders Equity1,072.23999.24910.35870.22835.12773.08
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1,072.23999.24910.35870.22835.12773.08
Total Liabilities & Stockholders Equity1,478.241,373.081,271.821,271.631,208.221,108.01
Book Value Per Share18.2617.1915.7315.0714.5013.44
Tangible Book Value Per Share17.0415.8614.2913.5312.8411.67
Full-Time Employees---293--
Price to Book Ratio1.842.311.862.582.052.52
Return on Assets13.3014.6112.5113.9817.3818.40
Return on Equity18.7320.4617.8620.7525.9327.58
Return on Invested Capital4.006.633.082.215.174.29
Quick Ratio3.423.453.563.583.723.80
Current Ratio3.443.483.583.603.753.84

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income48.2075.4332.4922.4950.8739.78
Depreciation5.975.975.977.435.975.97
Other Funds (Non Cash)33.099.9842.8014.8225.6426.57
Funds from Operations82.6588.1877.3952.1178.5965.83
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-5.964.25-49.6374.0430.1413.50
Cash from Operating Activities76.6992.4327.76126.15108.7379.33
Capital Expenditures0.000.000.00-19.36-0.07-0.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments7.68-131.50-151.651.72-4.72-4.58
Purchase of Investments-38.42-152.53-179.00-18.84-24.28-23.90
Sale Or Maturity of Investments46.0921.0327.3520.5619.5619.32
Other Uses0.000.00-32.000.000.00-15.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities7.68-131.50-183.65-17.63-4.79-19.59
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock17.965.520.352.650.752.10
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock17.965.520.352.650.752.10
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-5.00-5.00-5.00-5.00-3.75-3.75
Change in Long Term Debt-5.00-5.00-5.00-5.00-3.75-3.75
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-5.00-5.00-5.00-5.00-3.75-3.75
Net Financing Active Other Cash Flow0.00-1.07-2.56-0.660.00-1.03
Other Financing Activities Uses0.00-1.07-2.56-0.660.00-1.03
Cash from Financing Activities12.96-0.56-7.22-3.02-3.00-2.69
Net Change in Cash97.33-39.63-163.10105.50100.9557.05
Free Cash Flow76.6992.4327.76126.04108.6679.32
Price to Free Cash Flow7.266.034.826.315.457.14

Revenue breakdown

Pharmaceutical Preparations2024: 714.73M 2025: 868.45M
United States2024: 714.73M 2025: 868.45M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3013.17%6.7M50.6M951.78K
2026-10-1510.78%5.4M50.2M905.29K
2026-09-3011.02%5.5M50.2M885.75K
2026-09-159.22%4.6M50.2M833.74K
2026-08-3110.30%5.2M50.1M807.49K
2026-08-148.25%4.1M50.1M827.50K
2026-07-318.87%4.5M50.7M823.40K
2026-07-1510.15%5.1M50.4M855.96K
2026-06-309.15%4.6M50.4M831.58K
2026-06-159.22%4.6M50.4M816.93K
2026-05-2911.79%5.9M50.4M785.17K
2026-05-1513.14%6.6M50.4M995.16K
2026-04-3013.66%6.9M50.5M951.09K
2026-04-1514.44%7.3M50.5M860.56K
2026-03-3115.21%7.6M50.3M881.32K
2026-03-1315.16%7.6M50.3M856.68K
2026-02-2715.81%7.9M50.3M852.61K
2026-02-1310.76%5.4M50.3M667.34K
2026-01-3011.60%5.7M48.9M750.41K
2026-01-1512.24%6.0M49.0M794.50K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call25.006.6010.800.002.9060.000.000.853-0.1340.013
call27.504.108.300.002.3440.000.000.815-0.1210.015
call30.001.705.600.001.7010.000.000.757-0.1030.017
call32.500.204.100.001.6390.000.000.611-0.1100.021
call35.000.002.700.651.50212.000.000.483-0.1700.022
call37.500.001.850.051.4931390.000.372-0.1590.021
call40.000.002.150.201.41278.000.000.262-0.1290.018
call42.500.002.151.551.6354.000.000.235-0.1410.017
call45.000.002.151.101.8842610.000.214-0.1550.016
call47.500.001.300.502.0857.000.000.200-0.1640.015
call50.000.002.150.502.2689.000.000.189-0.1720.015
call55.000.002.150.352.5942.000.000.172-0.1860.014
call60.000.002.150.852.8771.000.000.161-0.1970.013
put25.000.002.150.002.0430.000.00-0.146-0.1300.013
put27.500.001.350.001.7620.000.00-0.202-0.1330.016
put30.000.001.300.651.14425.000.00-0.243-0.0990.017
put32.500.002.900.770.68569.001.00-0.389-0.1070.021
put35.000.504.202.501.54251.000.00-0.517-0.1670.022
put37.502.256.104.311.65548.000.00-0.628-0.1550.021
put40.004.708.506.201.92652.000.00-0.738-0.1250.018
put42.507.2011.005.202.2020.000.00-0.766-0.1390.017
put45.009.7013.500.002.4460.000.00-0.786-0.1500.016
put47.5012.1016.000.002.6670.000.00-0.800-0.1590.015
put50.0014.6018.500.002.8690.000.00-0.811-0.1670.015
put55.0019.6023.500.003.2270.000.00-0.828-0.1800.014
put60.0024.7028.500.003.5370.000.00-0.839-0.1900.013

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-308-K/A2026-10-12SEC
2026-10-27SCHEDULE 13G/ASEC
2026-10-138-KCurrent report2026-10-12SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-18144Filing for proposed sale of securities under Rule 144.SEC
2026-09-17144Filing for proposed sale of securities under Rule 144.SEC
2026-09-16144Filing for proposed sale of securities under Rule 144.SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-08144Filing for proposed sale of securities under Rule 144.SEC
2026-09-04144Filing for proposed sale of securities under Rule 144.SEC
2026-08-07144Filing for proposed sale of securities under Rule 144.SEC
2026-08-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-048-KCurrent report2026-08-04SEC
2026-07-31SCHEDULE 13GSEC
2026-07-28SCHEDULE 13G/ASEC
2026-07-223Initial statement of beneficial ownership of securities2026-07-16SEC
2026-07-168-KCurrent report2026-07-16SEC
2026-07-02144Filing for proposed sale of securities under Rule 144.SEC
2026-06-30144Filing for proposed sale of securities under Rule 144.SEC
2026-06-26144Filing for proposed sale of securities under Rule 144.SEC
2026-06-24144Filing for proposed sale of securities under Rule 144.SEC
2026-06-09144Filing for proposed sale of securities under Rule 144.SEC
2026-06-05144Filing for proposed sale of securities under Rule 144.SEC
2026-06-04144Filing for proposed sale of securities under Rule 144.SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-14SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-01SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-14SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-04-14SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09003.11M5
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-0100892.00K2
2025-12001.83M2
2025-1100119.95K1

Institutional holders

Manager% owned
BlackRock, Inc.12.27%
FMR LLC5.61%
VANGUARD PORTFOLIO MANAGEMENT LLC4.98%
DIMENSIONAL FUND ADVISORS LP4.55%
AMERICAN CENTURY COMPANIES INC4.39%
LSV ASSET MANAGEMENT3.79%
VANGUARD CAPITAL MANAGEMENT LLC3.64%
STATE STREET CORP3.21%
ARMISTICE CAPITAL, LLC2.70%
GEODE CAPITAL MANAGEMENT, LLC2.66%

Funds

Fund% owned
Avantis U.S. Small Cap Value ETF4.21%
iShares Core S&P Small-Cap ETF4.16%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.69%
iShares Russell 2000 ETF2.00%
VANGUARD SMALL-CAP INDEX FUND1.95%
VANGUARD SMALL-CAP GROWTH INDEX FUND1.13%
Fidelity Growth Company Fund0.90%
Fidelity Small Cap Index Fund0.85%
VANGUARD EXTENDED MARKET INDEX FUND0.80%
Fidelity Enhanced Small Cap Core ETF0.79%

OakChart. HRMY. Cached 15 minutes.